Exicure Sells GPC-100 Assets to GPCRT for KRW 6.5B

The Korean buyer will take over the GPC-100 program and assume obligations under the existing License and Collaboration Agreement at closing.

Updated on Nov. 10, 2026 in Biotech

Bold vector editorial illustration of a clear glass vial of amber liquid beside stacked wooden blocks on a slate surface, representing a biotech asset transfer.
Exicure agreed on November 4, 2026 to sell its GPC-100 program assets to Korea's GPCRT Inc. for about US$4.8 million, or KRW 6.5 billion. AI Illustration. Upload story photo >

Exicure, Inc. agreed on November 4, 2026 to sell its GPC-100 program assets to GPCRT Inc. for an aggregate cash purchase price of KRW 6.5 billion, approximately US$4.8 million. The deal transfers rights under a January 19, 2025 License and Collaboration Agreement with GPCR Therapeutics, Inc.

Why it matters

The sale is part of Exicure's ongoing evaluation of strategic alternatives aimed at maximizing stockholder value. The company says the transaction is expected to strengthen its financial position.

The purchase price is set at KRW 6.5 billion, with KRW 500 million already paid and credited against the total, KRW 2.0 billion due by November 16, 2026, and KRW 4.0 billion due at closing. The release does not disclose technical performance data beyond the Phase 2 trial completion in January 2026.

The players

Exicure, Inc.

Exicure is a publicly traded biotechnology company developing oligonucleotide-based therapeutics, which is selling the GPC-100 program as it weighs strategic options.

GPCRT Inc.

GPCRT Inc. is a South Korean company acquiring the GPC-100 program assets and assuming obligations under the existing license agreement.

The details

Exicure and its subsidiary GPCR Therapeutics USA Inc. signed an Intellectual Property, Asset and License Assignment Agreement with GPCRT Inc. GPC-100 is being evaluated in combination with propranolol for stem cell mobilization in patients with multiple myeloma, and GPCR USA completed its Phase 2 trial in January 2026. GPCR USA will remain a wholly owned Exicure subsidiary after closing.

Timeline

  1. January 19, 2025: License and Collaboration Agreement with GPCR Therapeutics was entered into.

  2. January 2026: GPCR USA completed its Phase 2 clinical trial of GPC-100.

  3. September 1, 2026: Cutoff after which GPCRT bears GPC-100 program costs.

  4. November 4, 2026: Asset assignment agreement was signed.

  5. November 16, 2026: KRW 2.0 billion payment is due from GPCRT.

Market Landscape

The transaction reflects a pattern in which small U.S. biotechs divest clinical-stage programs to Asia-based companies that can carry them forward after a Phase 2 readout. It also shows how a licensed program can be transferred mid-agreement, with the new owner taking on milestone and royalty obligations.

For shareholders of Exicure, the sale is intended to strengthen the company's finances, though the closing still depends on approvals and a release from GPCR Therapeutics. The transaction does not change any product available to patients or consumers.

The takeaway

Asset sales like this show how small biotechs can monetize early programs while keeping their remaining business intact. Investors watching such deals should track whether promised payments and closing conditions are actually met.

Further reading

For more on how drug programs change hands across borders, see our Biotech coverage.